Babesia duncani as a Model Organism to Study the Development, Virulence, and Drug Susceptibility of Intraerythrocytic Parasites In Vitro and In Vivo

被引:16
|
作者
Pal, Anasuya C. [1 ]
Renard, Isaline [1 ]
Singh, Pallavi [1 ]
Vydyam, Pratap [1 ]
Chiu, Joy E. [1 ]
Pou, Sovitj [2 ]
Winter, Rolf W. [2 ]
Dodean, Rozalia [2 ]
Frueh, Lisa [2 ]
Nilsen, Aaron C. [2 ]
Riscoe, Michael K. [2 ]
Doggett, J. Stone [2 ]
Ben Mamoun, Choukri [1 ]
机构
[1] Yale Sch Med, Infect Dis Sect, Dept Internal Med, New Haven, CT USA
[2] Vet Affairs Portland Hlth Care Syst, Portland, OR USA
基金
美国国家卫生研究院;
关键词
babesiosis; Babesia duncani; erythrocytes; Apicomplexa; parasite; INFECTION; MICE; WA1; PIROPLASM;
D O I
10.1093/infdis/jiac181
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We describe an optimized Babesia duncani in culture-in mouse model that combines continuous parasite replication in human erythrocytes and lethal infection in mice. Study findings support the use of this model to study Babesia virulence and develop new therapies for human babesiosis. Human babesiosis is a malaria-like illness caused by tick-borne intraerythrocytic Babesia parasites of the Apicomplexa phylum. Whereas several species of Babesia can cause severe disease in humans, the ability to propagate Babesia duncani both in vitro in human erythrocytes and in mice makes it a unique pathogen to study Babesia biology and pathogenesis. Here we report an optimized B. duncani in culture-in mouse (ICIM) model that combines continuous in vitro culture of the parasite with a precise model of lethal infection in mice. We demonstrate that B. duncani-infected erythrocytes as well as free merozoites can cause lethal infection in C3H/HeJ mice. Highly reproducible parasitemia and survival outcomes could be established using specific parasite loads in different mouse genetic backgrounds. Using the ICIM model, we discovered 2 new endochin-like quinolone prodrugs (ELQ-331 and ELQ-468) that alone or in combination with atovaquone are highly efficacious against B. duncani and Babesia microti.
引用
收藏
页码:1267 / 1275
页数:9
相关论文
共 39 条
  • [21] PHARMACOKINETIC DRUG-DRUG INTERACTIONS BETWEEN ETHAMBUTOL AND METFORMIN, PBPK-MODEL-BASED ASSESSMENT AS IN VITRO TO IN VIVO EXTRAPOLATION STUDY.
    Parvez, M.
    Kaisar, N.
    Shin, H.
    Ghim, J. -L.
    Shin, J. -G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S8 - S9
  • [22] PHARMACOKINETIC DRUG-DRUG INTERACTIONS BETWEEN ETHAMBUTOL AND METFORMIN, PBPK-MODEL-BASED ASSESSMENT AS IN VITRO TO IN VIVO EXTRAPOLATION STUDY.
    Parvez, M.
    Kaisar, N.
    Shin, H.
    Ghim, J. -L.
    Shin, J. -G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S43 - S44
  • [23] Are pigs a suitable animal model for in vivo metabolism studies of new psychoactive substances? A comparison study using different in vitro/in vivo tools and U-47700 as model drug
    Nordmeier, Frederike
    Doerr, Adrian
    Laschke, Matthias W.
    Menger, Michael D.
    Schmidt, Peter H.
    Schaefer, Nadine
    Meyer, Markus R.
    TOXICOLOGY LETTERS, 2020, 329 : 12 - 19
  • [24] From in vitro EC50 to in vivo dose–response for antiretrovirals using an HIV disease model. Part II: Application to drug development
    Jing Fang
    Pravin R. Jadhav
    Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39 : 369 - 381
  • [25] In Vitro-In Vivo Correlation of Blood–Brain Barrier Permeability of Drugs: A Feasibility Study Towards Development of Prediction Methods for Brain Drug Concentration in Humans
    Ryo Ito
    Hanae Morio
    Tomoyo Baba
    Yasuyuki Sakaguchi
    Naomi Wakayama
    Ryuto Isogai
    Yoshiyuki Yamaura
    Takafumi Komori
    Tomomi Furihata
    Pharmaceutical Research, 2022, 39 : 1575 - 1586
  • [26] From in vitro EC50 to in vivo dose-response for antiretrovirals using an HIV disease model. Part II: Application to drug development
    Fang, Jing
    Jadhav, Pravin R.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2012, 39 (04) : 369 - 381
  • [27] Does pre-exposure of Aspergillus fumigatus to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively?: A study in a fly model of aspergillosis
    Lamaris, G. A.
    Ben-Ami, R.
    Lewis, R. E.
    Kontoyiannis, D. P.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 62 (03) : 539 - 542
  • [28] Characterization and Compatibility Studies of Different Rate Retardant Polymer Loaded Microspheres by Solvent Evaporation Technique: In Vitro-In Vivo Study of Vildagliptin as a Model Drug
    Dewan, Irin
    Islam, Swarnali
    Rana, Md. Sohel
    JOURNAL OF DRUG DELIVERY, 2015, 2015
  • [29] Evaluation of drug penetration into the brain:: A double study by in vivo Imaging with positron emission tomography and using an in vitro model of the human blood-brain barrier
    Josserand, V
    Pélerin, H
    de Bruin, B
    Jego, B
    Kuhnast, B
    Hinnen, F
    Ducongé, F
    Boisgard, R
    Beuvon, F
    Chassoux, F
    Daumas-Duport, C
    Ezan, E
    Dollé, F
    Mabondzo, A
    Tavitian, B
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 316 (01): : 79 - 86
  • [30] Development of a Population Pharmacokinetics-Based in vitro-in vivo Correlation Model for Drugs with Site-Dependent Absorption: the Acyclovir Case Study
    Shin, Soyoung
    Kim, Tae Hwan
    Lee, Da Young
    Chung, Seung Eun
    Lee, Jong Bong
    Kim, Do-Hyung
    Shin, Beom Soo
    AAPS JOURNAL, 2020, 22 (02):